Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype
- PMID: 18955449
- DOI: 10.1200/JCO.2008.17.7725
Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype
Comment on
-
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955458 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
